ArticleImmunology1993
Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.
Article in Immunology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- CD4+ T cells promote the pathogenesis of Staphylococcus aureus pneumonia.The Journal of infectious diseases · 2015Article
- Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.International journal of biological sciences · 2009Article
- Genetically engineered superantigens as tolerable antitumor agents.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- The tumour associated cell surface antigen A6H is costimulatory for human CD4+ but not CD8+ T cells.Immunology · 1997Article
- T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.Immunology · 1997Article
- Major histocompatibility complex class I molecule serves as a ligand for presentation of the superantigen staphylococcal enterotoxin B to T cells.Proceedings of the National Academy of Sciences of the United States of America · 1996Article
- Staphylococcal enterotoxins modulate interleukin 2 receptor expression and ligand-induced tyrosine phosphorylation of the Janus protein-tyrosine kinase 3 (Jak3) and signal transducers and activators of transcription (Stat proteins).Proceedings of the National Academy of Sciences of the United States of America · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The superantigen Staphylococcal enterotoxin A (SEA) conjugated to tumour-specific monoclonal antibodies (mAb) directs T cells to lyse tumour cells in the absence of major histocompatibility complex (MHC) class II. In contrast, the conjugate bound to MHC class II-negative tumour cells did not activate resting T cells to proliferate. The SEA-C215 mAb conjugate, when presented on the CA215 antigen-expressing Colo205 cells, required either signalling with CD28 mAb or CHO cells expressing the natural CD28 ligand, B7, to activate the T cells. The CD28/B7 co-stimulatory effect was further enhanced when the B7 and the tumour antigen were present on the same cell, decreasing the superantigen amount required for activation with a factor of 10(4). No influence of B7 was seen when the single CA215 or double CA215/B7 transfectants were used as targets for superantigen conjugate-dependent cytotoxicity. This suggests that the low affinity T-cell receptor (TcR) interaction of superantigen in the absence of MHC class II antigens is sufficient for induction of cytotoxicity but requires additional CD28/B7 signalling to result in proliferation of resting T cells.
Indexed as
Identifiers
7505257PMC1422194W2413475714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.